FHTX · Foghorn Therapeutics Inc.
$2.08
+0.11 (+5.58%)
At close · Oct 7
Return incl. dividend (before tax)
Market Cap
$122.33M
Shares
59.39M
Volume · Oct 7
293.07K
Avg daily vol (3M)
631.8K
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$1.97
Open$2.00
Day$1.84–2.02
52W close$1.97–7.07
Avg vol 30d969K
Short int2.0M · 3.4% float · 5.2d
Short vol33%
Last earningsAug 10, 2021
DataOct 2020–Oct 2026
Filing10-Q · Aug 6
Up next
filed Aug 6, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
$36.74M
Trailing 12 months
Net income (TTM)
−$64.58M
Trailing 12 months
Revenue growth YoY
+112.7%
Year over year
Operating margin
-198.0%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
-68.9%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+12.1%
Year over year · more shares
Price change (1Y)
-56.5%
Trailing year
Short interest
3.4%
Latest settlement · 5.2 days to cover
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Strong Sell
Momentum
Very Weak
Sentiment
Bearish
Fundamentals
Strong
Quant / Vol
Very High
Market backdrop
VIX 15 · calm
Equity put/call 0.57
Technical
price trend
50 / 200-day cross
Death cross
Price vs 200-day avg
−61%
below
Price vs 50-day avg
−60%
below
RSI (14)
12
oversold
MACD trend
Negative
52-week position
0%
near low
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−59%
trailing
6-month return
−60%
trailing
YTD return
−64%
this year
Relative strength
−71%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
Death cross
50d $5 › 200d $5 — 200d above 50d
Institutional flow
Distributing
-3% holders QoQ · +14 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
3.36% of float · ▲ +1.2% MoM · 5.2 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
102 holders — near 3-yr high, broad support
Squeeze score
50
elevated · 0–100
Fundamentals
Revenue growth
+37%
Y/Y
EPS growth
+25%
Y/Y
Free cash flow
$-86.1M
Balance sheet
$73.1M
net cash
Quant / Vol
risk profile
Volatility
84%
annualized · 1-yr
Max drawdown
−72%
past year
ATR
19.7%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Strong Sell
50 / 200-day cross
Death cross
Bearish
Price vs 200-day avg
−61%
Bearish
Price vs 50-day avg
−60%
Bearish
RSI (14)
12
Neutral
MACD trend
Negative
Bearish
52-week position
0%
Bearish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bearish · 3 of 6
Trend (MA cross)
Death cross
50d $5 › 200d $5 — 200d above 50d
Institutional flow
Distributing
-3% holders QoQ · +14 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
3.36% of float · ▲ +1.2% MoM · 5.2 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
102 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $2
Now $2 · 0%
Range high $7
vs 200-day avg -61%
vs 50-day avg -60%
50-day below 200-day death cross
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
FHTX
this stock
Foghorn Therapeutics Inc.
|
$122.33M | -63.5% | +36.8% | — | 3.4% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$133.37B | +10.8% | +46.2% | 30.7 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$81.13B | -4.3% | +20.8% | 19.5 | 2.5% |
|
MRNA
Moderna, Inc.
|
$79.40B | +535.7% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$61.25B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| FHTX | -44.0% | -59.2% | -59.6% | -44.8% | -63.5% |
| SPY | +2.0% | +1.7% | +11.3% | +2.2% | +14.3% |
| vs SPY | -46.0% | -60.9% | -70.9% | -47.0% | -77.8% |